Mark Elliott Boulding
EXEC. VP AND CLO · PTC THERAPEUTICS, INC.
- 2024
- Oct 13, 2026
- 19
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Mark Elliott Boulding files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Neil Gregory Almstead - $16.35M in PTCT purchases and sales in the last 12 months
- Michael Schmertzler - $6.47M in PTCT purchases and sales in the last 12 months
- Matthew B. Klein - $3.60M in PTCT purchases and sales in the last 12 months
- Eric Pauwels - $2.61M in PTCT purchases and sales in the last 12 months
- Emma Reeve - $2.49M in PTCT purchases and sales in the last 12 months
- Allan Steven Jacobson - $2.13M in PTCT purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Mark Elliott Boulding?
Mark Elliott Boulding is a corporate insider, tracked as EXEC. VP AND CLO of PTC THERAPEUTICS, INC. (PTCT). InsiderAlpha holds 19 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Mark Elliott Boulding submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Mark Elliott Boulding been buying or selling stock?
Recorded transactions: 0 open-market purchases and 80 open-market sales ($14.11M) across all tracked filings.
